secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2023-11-15T23:59:59+00:00
Accession:  0001193125-23-277552
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences gets FDA IND clearance for Duchenne gene therapy SGT-003; Phase 1/2 trial planned
--------------------------------------------------------------------------------

- FDA clears IND for SGT-003, a next-generation microdystrophin gene therapy for Duchenne muscular dystrophy.
- Phase 1/2 trial (SGT-003-101) will be first-in-human, open-label, multicenter; dose 1E14vg/kg as single IV infusion.
- Cohort 1 enrolls patients aged 4 to <6 years; minimum 3 patients per cohort with potential expansion; 5-year follow-up.
- SGT-003 uses capsid AAV-SLB101 with R16/R17 nNOS-binding domains; preclinical data showed improved biodistribution vs AAV9.
- Company expects to submit for IRB approval and commence patient screening shortly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312523277552/0001193125-23-277552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312523277552/d852507d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-277552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer